Pharma layoffs do not necessarily signal declining pharmaceutical demand: the biopharmaceutical industry can experience workforce reductions while drug sales grow because companies are simultaneously restructuring operations, prioritizing pipelines, adopting automation, and reducing costs.
Biotech and pharmaceutical layoffs have multiple causes: workforce reductions have been linked to a difficult biotech funding environment, clinical trial failures, strategic pipeline prioritization, operational restructuring, asset divestitures, M&A, and company wind-downs rather than a single industry-wide contraction.
Pharma layoffs affect different functions for different reasons: reductions can include R&D, manufacturing, human resources, finance, IT, sales, and other support functions, with the mix depending on whether a company is restructuring, discontinuing a clinical program, divesting assets, or ceasing operations.
Pharmaceutical manufacturing can face layoffs and a talent shortage simultaneously: restructuring can eliminate positions at individual companies while manufacturers and CDMOs continue to need specialized employees with relevant GMP, manufacturing, quality, technical, and drug-development experience.
Biopharma employment is only one measure of pharmaceutical industry health: drug sales, clinical pipeline progression, R&D investment, financing, productivity, and new-product development provide important context for interpreting layoffs and hiring trends.
The current market paradox
The pharmaceutical industry, once buoyed by the unprecedented demand and rapid innovation triggered by the COVID-19 pandemic, is currently readjusting to a post-COVID world, which has brought its own challenges, including a wave of layoffs that has swept across the biotech and pharma landscape in the past few years. This undercurrent of job reductions and corporate restructuring echoes the industry’s reflex to recalibrate in response to market pressures and strategic realignments, which appears at odds with forecasts of robust drug sales and potential market growth.
Both large pharmaceutical companies and smaller biotech firms have faced significant layoffs.[1][2] For instance, Pfizer and Roche have reduced their workforce as part of broader restructuring efforts.[3] In the biotech sector, companies like Novavax, Gossamer Bio, and ADC Therapeutics announced significant layoffs.[4] The layoffs are widespread, affecting various regions globally, with notable job cuts in Basel, Cambridge, and Dublin.
A number of discrete factors are contributing to these recent layoffs:[5]
Difficult funding environment. Some biotech companies, like Ring Therapeutics, faced challenges in securing adequate funding, which led to workforce reductions.
Strategic pivot/refocusing. Many companies underwent strategic changes, focusing on their most promising programs, which resulted in layoffs. For example, Allogene Therapeutics and Senti Biosciences significantly reduced their staff to concentrate on specific therapies.
Clinical trial failures. Companies like AlloVir and Allakos reduced their workforce after facing clinical trial setbacks.
Operational reorganization. Pfizer and Thermo Fisher Scientific, among others, implemented layoffs as part of operational restructuring to improve efficiency and optimize R&D spending.
Liquidation or wind-down. Smaller companies like Catamaran Bio and ObsEva had to wind down operations due to insurmountable challenges, laying off all employees.
Asset sales or divestitures. Layoffs also occurred in conjunction with strategic asset sales or divestitures, as seen with 2seventy bio and Catalent.
The specific positions cut vary widely across companies and are often not publicly detailed. However, the layoffs include both R&D positions and administrative and support roles, particularly in companies undergoing operational restructuring or those that are ceasing operations altogether. These layoffs can have a cascading effect on the industry, as the loss of specialized talent in areas like R&D can impact the pace of innovation and drug development in the long term.
R&D. Many biotech companies, after unsuccessful clinical trials or strategic refocusing, have had to cut back on their R&D staff, in large part because unsuccessful trials can lead to the discontinuation of programs that these employees were hired to support.
Support functions. In an effort to streamline operations and reduce costs, administrative and ancillary support functions are often targeted for layoffs. This can include positions in human resources, marketing, finance, and IT, especially when companies are trying to pivot their strategies or conserve cash.
Manufacturing. For some companies, such as those winding down operations or narrowing their focus to a few drug candidates, manufacturing roles have been affected as the demand for production decreases.
Sales and commercial teams. In cases where a company is restructuring due to poor sales performance or divesting certain assets, sales and commercial teams may be reduced to align with the revised business scope.
While drug sales are predicted to increase, the industry is also undergoing a transformation aimed at optimizing operations and focusing on the most promising drug candidates. This realignment means that even though overall drug sales might increase, the workforce required may be lower due to increased efficiencies, automation, and strategic focus.[5]
Streamlined operations. Companies are optimizing their workforce to align with strategic goals, which may lead to increased profitability and thus contribute to higher drug sales. This lean approach can, paradoxically, require fewer employees while still driving growth.
Shift in therapeutic focus. As companies pivot toward more profitable or promising therapeutic areas, this can lead to increased sales in those segments while rendering other areas and their corresponding teams redundant.
Increased automation and digital transformation. The industry is increasingly adopting automation and digital tools, which can improve efficiency and reduce the need for certain roles while also potentially leading to an increase in sales due to improved targeting and engagement strategies.
Market consolidation. Increased M&A activity can create redundancies in the workforce, leading to layoffs, but also potentially leading to a more robust product portfolio and sales growth for the consolidated entities.
Cost management. Layoffs can be a part of cost-cutting measures to manage the high expenses associated with drug development. By reducing overhead costs, companies can potentially increase their profitability, indirectly contributing to a healthier bottom line and increased sales.
Overall, the biopharma market is showing signs of recovery but remains under pressure due to various challenges, including funding difficulties and the aftershocks of the pandemic. The job market competition is fierce, with a significant slowdown in hiring, according to BioSpace’s 2024 U.S. Life Sciences Employment Outlook report.[6] However, there’s a sense of cautious optimism as companies adjust to the new market realities, streamline operations, and focus on high-potential projects.
It’s worth noting that the industry’s health isn’t solely reflected in workforce numbers; innovation, pipeline progression, and sales performance are also critical indicators. Despite the layoffs, companies are still making strategic investments in promising areas of research and drug development, indicating a complex yet evolving market landscape.
FAQs
Why are pharmaceutical and biotech companies laying off employees?
Pharmaceutical and biotech companies are laying off employees primarily because of restructuring, funding constraints, clinical setbacks, and changes in strategic priorities. Other drivers include pipeline prioritization, cost reduction, mergers and acquisitions, asset divestitures, automation, and company closures. Layoffs therefore reflect multiple company-specific pressures rather than a single decline across the pharmaceutical industry.
Why are pharma layoffs happening if pharmaceutical sales are growing?
Pharma layoffs can occur while pharmaceutical sales grow because revenue growth and workforce growth are not directly linked. Pharmaceutical companies can increase productivity by prioritizing higher-value drug candidates, restructuring R&D, automating operations, divesting noncore assets, consolidating functions after acquisitions, and reducing overhead while continuing to generate greater sales from successful products.
Which jobs are most affected by pharma and biotech layoffs?
Pharma and biotech layoffs can affect R&D, manufacturing, commercial, and corporate support positions. Failed clinical programs frequently affect research and development teams, while restructuring can eliminate roles in human resources, finance, marketing, and IT. Manufacturing and commercial positions may also be reduced following divestitures, pipeline changes, declining product demand, or company closures.
Is there still a talent shortage in pharmaceutical manufacturing?
Pharmaceutical manufacturing can experience a talent shortage even during periods of widespread pharma layoffs. Layoffs may occur in specific companies, therapeutic programs, geographies, or functions, while pharmaceutical manufacturers and CDMOs still require workers with specialized GMP manufacturing, quality, engineering, process development, automation, validation, and regulatory experience that cannot necessarily be replaced by displaced workers from other functions.
How do biotech funding conditions affect pharma layoffs?
Difficult biotech funding conditions can directly increase layoffs by forcing companies to conserve cash and extend their financial runway. Development-stage biotechnology companies often depend on venture financing, public markets, partnerships, or other external capital to fund clinical trials and R&D, making workforce reductions, pipeline prioritization, and program discontinuations potential responses when capital becomes harder to obtain.
How do mergers and acquisitions cause pharmaceutical layoffs?
Pharmaceutical mergers and acquisitions can cause layoffs when the combined companies have overlapping employees, facilities, programs, or corporate functions. After an acquisition, companies may consolidate R&D, manufacturing, commercial, finance, human resources, and administrative operations, eliminating redundant positions while reallocating capital toward higher-priority products, therapeutic areas, manufacturing networks, or development programs.
What is the outlook for pharmaceutical and biotech hiring?
The pharmaceutical and biotech hiring outlook depends increasingly on company finances, pipeline priorities, and specialized talent requirements rather than uniform industry growth. Even when overall biopharma sales expand, restructuring, automation, and cost controls can constrain headcount, while companies may continue hiring selectively for high-priority R&D, pharmaceutical manufacturing, quality, engineering, regulatory, and technical roles.
